Wed, Jul 3, 2024 9:35 AM
IPO Analysis: Emcure Pharma has better-listed pharma alternatives
A Flip by Riya Sharma
Vertex Pharmaceuticals has delivered a remarkable 15.1% average annual return since its 1991 IPO, with a 10,310% growth, driven by its success in developing medicines for rare diseases, including cystic fibrosis. The company's focus on targeting underlying causes of diseases, combined with its innovation culture and vision, makes it a solid buy-and-hold-forever pick.
Open Flip
Awign has raised Rs 203.5 crore or $24.5 million from Japan-based Mynavi Corporation, which will now control a 73% stake in the Bengaluru-based HR tech startup, according to the company’s filings with RoC. In May, the board at Awign passed a special resolution to issue 11,485 Series C CCPS at an issue price of Rs 1,77,206 each to raise Rs 203.5 crore or $24.5 million, its regulatory filings show.
Open Flip
Foreign investors infused $3.1 billion in Indian real estate during January-June 2024, accounting for 65% of total institutional investment. Total institutional investment rose 62% to $4,760 million in January-June 2024 from $2,939 million in the same period last year. The warehousing sector led with a 34% share, followed by residential at 33% and office at 27%.
Open Flip
